Findings

What do systematic reviews say?

630 questions · 634 findings · 285 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 316 · 49.8%GRADE not reported 40 · 6.3%Very low 95 · 15%Low 111 · 17.5%Moderate 60 · 9.5%High 12 · 1.9%

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

COGNITIVE BEHAVIOUR THERAPY + MOTIVATIONAL INTERVIEWING vs usual care

Quality of life / life satisfaction: Brief Quality of Life Scale · people with both severe mental illness and substance misuse

1 finding from 1 review

Psychosocial interventions for people with both severe mental illness and substance misuse 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 110 participants
Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 946 participants
Low

Physiotherapy and occupational therapy vs placebo

Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments Functional Independence Measure (total). Scale from: 0 to 126. Higher scores indicate less disability · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Very low

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 55 participants
Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
Low

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs treatment

Average change in quality of life/satisfaction · patients with SCHIZOPHRENIA AND CANNABIS USE

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1139 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention vs non‐directive reflective listening + supportive intervention

Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 382 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 599 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life ‐ (EuroQol) EQ‐5D‐3L Index Score (total score): absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1061 participants
Moderate

ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs placebo

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sildenafil vs placebo

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Group B cognitive behavioural therapy: cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone vs needs‐based intervention

QoL · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low